Health

HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND’S 185TH ANNIVERSARY

Punch commemorates its 185-year history with the launch of Punch Princesas Edición Limitada 2025, a new vitola that revives a popular format from the 1960s.This Limited Edition…

7 days ago

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

1 week ago

ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…

1 week ago

Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders

BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far more quietly than many people realise. Early indicators…

1 week ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…

1 week ago

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…

1 week ago

EpiEndo Pharmaceutical’s ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients

ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients Glasmacinal, a novel macrolide, was well…

1 week ago

Fitterfly (a division of PB Health) Secures Patent for PGR Technology to Drive Better Diabetes Outcomes

In an industry first, Fitterfly by PB Health has secured a Govt. of India patent for its Personalised Glycemic Response…

1 week ago

Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American Customer Value Leadership Recognition for Excellence in Patient-Centered Care Delivery

Frost & Sullivan recognizes Health Recovery Solutions for delivering adaptable, outcomes-driven, technology-enabled longitudinal care modelsSAN ANTONIO, Dec. 2, 2025 /PRNewswire/…

1 week ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

1 week ago